Study | Selection | Comparability | Outcome | Total score | |||||
Cohort | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Outcome not present at start |
Assessment of outcome | Adequacy of follow up of length | Adequacy of follow up | ||
DovjakP (2017)[9] | - | * | * | - | */- | * | * | * | 6 |
Young Y(2011)[11] | - | - | * | * | */- | - | * | * | 5 |
Palumbo AJ )2015([12] |
- | - | * | * | */- | - | * | * | 5 |
Badgeley MA (2019)[12] |
* | - | * | - | - | - | - | - | 2 |
Holleyman RJ )2022([14] |
- | - | * | - | */- | * | * | * | 5 |
BowerES (2017)[15] | - | - | * | - | */- | * | * | * | 5 |
Adunsky A )2012([16] |
- | - | - | */- | * | * | * | 4 | |
Vochteloo AJ (2013)[17] |
- | * | * | - | ** | * | * | * | 7 |
Trevisan C (2021)[18] |
- | * | * | - | */- | * | * | * | 6 |
Torpilliesi T (2012)[19] |
- | - | * | - | */- | * | * | * | 5 |
Prommik P (2022)[3] | - | - | * | - | - | * | * | * | 4 |
González‑Quevedo D (2022)[20] |
- | - | * | - | */- | * | * | * | 5 |
Strøm Rönnquist S (2022)[21] |
- | - | * | - | - | * | * | * | 4 |
De Jood SGe (2019)[22] |
- | - | * | - | - | * | * | * | 4 |
PROBERT N (2020)[23] |
* | - | * | - | */- | * | * | * | 5 |
Kjær N(2022)[24] | - | * | * | - | - | * | * | * | 5 |
Grundill M(2021)[25] | * | - | * | - | */- | * | * | * | 6 |
Inoue Tatsuro (2019)[26] | - | - | * | - | */- | * | * | * | 5 |
Jérôme V(2020)[27] | - | - | * | - | - | * | * | * | 4 |
Van de Ree CL (2019)[28] | - | - | * | - | */- | * | * | * | 5 |
KoYoungji (2019)[30] | - | - | * | - | - | * | * | * | 4 |
Beloosesky Y(2011)[31] | * | - | * | - | - | * | * | * | 5 |
KimuraA (2019)[32] | - | - | * | - | - | * | * | * | 4 |
Zhang C (2020)[33] | * | - | * | * | */- | * | * | * | 7 |
Rey-Rodriguez MM (2020)[34] |
* | - | * | - | */- | * | * | * | 6 |
Kim J (2019)[35] |
* | * | * | * | */- | * | * | * | 8 |
RappK (2008)[36] |
* | * | * | * | */- | * | * | * | 8 |
Glinkowski W(2019)(37] | * | - | * | - | - | * | * | * | 5 |
Northuis CA (2020)[38] |
- | - | - | - | ** | - | * | * | 4 |
Zheng JQ (2017)[39] |
* | * | * | - | ** | * | * | * | 8 |
Huang SW )2016)[41] |
* | - | * | - | ** | * | * | * | 7 |
Vala CH (2020)[42] |
* | * | * | * | ** | * | * | * | 9 |
Isaia GC (2011)[43] |
- | - | * | * | - | * | * | * | 5 |
Furuya T(2013)[44] | * | - | * | - | - | - | * | * | 4 |
Chevalley T(2007)[45] | - | - | * | - | */- | * | * | * | 5 |
Videla-Cés M, et al(2017)[46] | * | - | * | - | - | * | * | * | 5 |
Cross-sectional |
Selection | Compare ability | Outcome | Total score | |||||
Representativeness of the sample | Sample size | Non-respondents | Ascertainment of the exposure (risk factor) | Assessment of the outcome: | Statistical test: | ||||
Da Silva AC (2022)[40] | * | - | - | - | - | ** | * | 4 | |
Monaco M(2006)[10] | * | * | - | ** | * | ** | * | 8 |
Incidence cumulative | Incidence rate ratio(IRR) | Incidence (%) | Incidence rate in 10000 | Incidence rate in 1000 | Incidence rate in 100000 | N (%) |
Prevalence | Sex & sample size | Age(years) | Country | Type of study | First author/Year (Reference number) |
|
63 | MF= 238 |
>50 | Austria | cohort | Dovjak P (2017)[9] |
||||||||
57 | F=200 | 79.5±7.5 | Italy | cross-sectional | Monaco M (2006)[10] |
||||||||
18 | F=383 | 65-74 | USA | prospective | Young Y (2011)[11] |
||||||||
26 | 304 | 75-84 | |||||||||||
55 | 279 | >85 | |||||||||||
2.0 | 2.3 | F= 80014 |
50-79 | USA | cohort | Palumbo AJ )2015) [12] |
|||||||
3 | MF= 9024 |
50->80 | South Australia | cohort | Badgeley MA (2019)[13] |
||||||||
Displaced intracapsular=51.8 | MF= 42630 |
>60 | England | cohort | Holleyman RJ )2022)[14] |
||||||||
Undisplaced intracapsular=6.9 | |||||||||||||
Intertrochanteric=35.4 | |||||||||||||
Subtrochanteric=5.9 | |||||||||||||
Femoral Neck=48.5 | MF= 241 |
60≤ | USA | longitudinal |
Bower ES (2017)[15] |
||||||||
Intertrochanteric =41.5 |
|||||||||||||
Subtrochanteric=5.0 | |||||||||||||
Extracapsular=61 | MF =1114 |
65≤ | Israel | retrospective cohort | Adunsky A )2012)[16] |
||||||||
Intracapsular=39 | |||||||||||||
Neck of femur fracture=58.1 | MF= 1014 |
65-89 | USA | cohort | Vochteloo AJ (2013)[17] |
||||||||
Inter-) Trochanteric fracture=39.2 | MF=1014 | 65-89 | |||||||||||
Subtrochanteric fracture=2.8 | MF=1014 | 65-89 | |||||||||||
Non-operative treatment=1.1 | MF=1014 | 65-89 | |||||||||||
Neck of femur fracture=47.4 | MF=230 | >90 | |||||||||||
(Inter-) Trochanteric fracture=48.7 | MF=230 | >90 | |||||||||||
Subtrochanteric fracture=3.9 | MF=230 | >90 | |||||||||||
Non-operative treatment=3.0 | MF=230 | >90 | |||||||||||
Medial=60.9 | MF(2000-2001years)=192 | >65 | Italy | cohort | Trevisan C (2021)[18] | ||||||||
Lateral=39.1 | MF (2000-2001years)=192 | ||||||||||||
Medial=43 | MF (2015-2016years)=323 | ||||||||||||
Lateral=57 | MF(2015-2016years)=323 | ||||||||||||
Femoral neck=19.7 | MF=76 | >90 | Italy | retrospective | Torpilliesi T (2012)[19] |
||||||||
Intertrochanteric= 80.3 |
|||||||||||||
Femoral neck=51.2 | MF=11541 | >50 | Estonian | cohort | Prommik P (2022) [3] |
||||||||
Pertrochanteric=43.1 | |||||||||||||
Subtrochanteric=5.7 | |||||||||||||
(Before FLS implementation)Femoral neck=42.3 | MF=357 | >60 | Spain | cohort | González‑Quevedo D (2022)[20] |
||||||||
Trochanteric=49.6 | |||||||||||||
Subtrochanteric=8.1 | MF=744 |
||||||||||||
(After FLS implementation) Femoral neck=39.5 | |||||||||||||
Trochanteric=51.5 | |||||||||||||
Subtrochanteric= 9.0 |
|||||||||||||
Intracapsularfracture=58 | MF=218 | 18-59y | Denmark and Sweden | cohort | Strøm Rönnquist S (2022)[21] |
||||||||
Extracapsular fracture=42 | |||||||||||||
Femoral neck=46.8 | MF=216 | 65≤ | Netherlands | Retrospective and cross-sectional study | De Joode SG (2019)[22] |
||||||||
Pertrochanteric=53.2 | |||||||||||||
Femoral neck fracture(in 2008year)=53 | MF=78 | >35 | Sweden | cohort | PROBERTN (2020)[23] |
||||||||
Subtrochanteric femoral fracture in 2008year) =40 | |||||||||||||
pertrochanteric femoral fracture in 2008year)=8 | |||||||||||||
Femoral neck fracture in 2018year)=49 | MF=76 | ||||||||||||
Subtrochanteric femoral fracture in 2018year)=41 | |||||||||||||
pertrochanteric femoral fracture in 2018year)=11 | |||||||||||||
48.4 | MF=540 | 65≤ | Denmark | retrospective | Kjær N(2022)[24] | ||||||||
Crude=19.3 | Neck of femur=45.8 | MF=253 | 35≤ | South Africa | retrospective | Grundill M(2021)[25] | |||||||
Intertrochanteric=48.6 | |||||||||||||
Subtrochanteric=5.5 | |||||||||||||
Neck of fracture=50.4 | MF=274 | 65≤ | Japan | cohort | Inoue T (2019)[26] | ||||||||
Trochanteric=42.2 | |||||||||||||
Basal=3.3 | |||||||||||||
Subtrochanteric=4.1 | |||||||||||||
Intracapsular=34 | MF=140 | 80±12 | Belgium | Methodological study | Jérôme V (2020)[27] |
||||||||
Extracapsular=66 | |||||||||||||
55.5 | MF=925 | 65≤ | Netherlands | Cohort | Van de Ree CL (2019)[28] |
||||||||
Medial=46.2 | MF=1184 | 55≤ | Italy | NA | Scaglione M (2013)[29] |
||||||||
Lateral=53.8 | |||||||||||||
Intertrochanteric=54 | MF=1841 | 65≤ | South Korea | Prospective cohort | Ko Youngji (2019)[30] | ||||||||
Neck=39.3 | |||||||||||||
Subtrochanteric=3.1 | |||||||||||||
Atypical=3.6 | |||||||||||||
Intertrochanteric=56.1 | MF=155 | 67-103 | Israel | Cohort | Beloosesky Y (2011)[31] |
||||||||
Subcapital=34.8 | |||||||||||||
Subtrochanteric=9.0 | |||||||||||||
Femoral neck=56.7 | MF=497 | 60≤ | Japan |
Retrospectiv | Kimura A (2019)[32] |
||||||||
Trochanteric=40.6 | |||||||||||||
Sub-trochanteric=2.6 | |||||||||||||
Crud (in 2012)=148.75(115.32-182.19) | MF=190560 | 55≤ | China | Cohort |
Zhang C(2020)[33] | ||||||||
adjusted(in2012)=128.10(88.68-174.79) | |||||||||||||
Crud (in2016)=136.65(109.68-163.62) | |||||||||||||
Adjusted(in2016)=114.46(89.85-142.06) | |||||||||||||
228.0(204.5-251.6) | Extracapsular in men=50.6 in female=61.1 |
MF=359 | 50≤ | Spain |
prospective |
Rey-Rodriguez MM (2020)[34] |
|||||||
Intracapsular in men=49.4 in female=38.9 |
|||||||||||||
Brain disability =6.3 | Limb disability=5.9 | MF=90012 | 65≤ | korea | Cohort | Kim J (2019)[35] |
|||||||
Mental disabi lity=7.5 | Brain disability=6.3 | ||||||||||||
Visual disability=4.8 | |||||||||||||
Auditory impairment=4.7 | |||||||||||||
Mental retardation=5.3 | |||||||||||||
Mental disease=7.5 | |||||||||||||
Renal impairment=5.0 | |||||||||||||
Crud in female= 50.8(49.2-52.4) Crud in men=(32.7(30.0-35.4) |
M=16746 F=52946 |
65≤ | Germany | Cohort |
Rapp K(2008)[36] | ||||||||
Adjusted in female=39.3(37.7-40.9) Adjusted in men=26.0(23.3-28.7) |
|||||||||||||
Female=19.4 | MF=289230 | >50 | Poland | retrospective | Glinkowski W (2019)[37] |
||||||||
Men=14.2 | |||||||||||||
2.7 | F=4640 | 50-79y | USA | prospective | Northuis CA (2020)[38] | ||||||||
1.95(1.71-2.22) | Control group= 2.49 |
MF=68672 |
≥18 | Taiwan | Cohort | Zheng JQ (2017)[39] |
|||||||
Stork patients=4.85 | |||||||||||||
15.58 | MF=45645 | ≥60 | Brazil | Cross- sectional | Da Silva AC (2022)[40] |
||||||||
COPD patients=649 | patients with COPD=16239 | ≥51 | Taiwan | Cohort |
HuangSW )2016)[41] |
||||||||
Control=369 | |||||||||||||
patients without COPD=48717 | |||||||||||||
10.45 | MF=1783035 | 60-100y | Sweden | Cohort | Vala CH (2020)[42] |
||||||||
3.84 | MF=4269 | 50-85y | Italy | longitudinal | Isaia GC (2011)[43] |
||||||||
1.926 | MF=9720 | Japan | Cohort | Furuya T (2013)[44] |
|||||||||
2.99(2.80-3.18) | Femal= 455(439-471) |
MF=4115 | ≥50 | Geneva, Switzerland | Retrospective |
Chevalley T (2007)[45] |
|||||||
Men= 153(143-163) |
|||||||||||||
1.3 (0.9-1.8) |
MF=2625 | >64 | Spain | Retrospective | Videla-Cés M (2017)[46] |
||||||||
In2006= 175.9 |
MF=23075 | 81.0±11.7 y | Italy | NA | Di Giovann Pi (2019)[47] |
||||||||
In 2015= 179.3 |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution 4.0 International License. |